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Abstract Microglial activation is a key aspect of the
neuroinflammatory process in neurodegenerative disorders
including idiopathic and atypical parkinsonian disorders.
With positron emission tomography (PET) it has become
possible to image this phenomenon in vivo and over the
last years patterns of microglia activation corresponding
with the known distribution of neuropathological changes
in these disorders have been demonstrated using this
technique. In addition the effects of interventions aimed at
suppressing microglia activation as part of interventional
trials have successfully been demonstrated. Current
research aims at evaluating PET tracers for microglial
activation with more favorable properties than the proto-
typical [11C]-(R)-PK11195, as well as developing tracers
targeting additional parameters of the neuroinflammatory
process like astroglial function.
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Introduction
Inflammation is a reaction of living tissues to injury and
acute and chronic inflammation can be distinguished.
Acute inflammation comprises the immediate and early
response to an injurious agent and is basically a defensive
response that paves the way for repair of the damaged site.
Chronic inflammation results from stimuli that are persis-
tent. In the periphery, inflammation consists of leukocytic
infiltrates characterized by polymorphonuclear cells (neu-
trophils) and mononuclear cells (macrophages, lympho-
cytes, plasma cells).
Over the last years, the term ‘‘neuroinflammation’’ has
come into widespread use. This term generally denotes
chronic, CNS-specific, inflammation-like glial responses
that do not reproduce the classic characteristics of inflam-
mation in the periphery but that may cause and/or sustain
neurodegenerative events including plaque formation, dys-
trophic neurite growth, and excessive tau phosphorylation
[1]. Neuroinflammation has been implicated in chronic
unremitting neurodegenerative diseases such as Parkinson’s
and Alzheimer’s disease; diseases that historically have not
been regarded as primary inflammatory disorders. This new
understanding has come from rapid advances in the field of
microglial and astroglial neurobiology over the past
15–20 years. These advances have led to the recognition that
glia, particularly microglia, respond to tissue insults with a
complex array of inflammatory cytokines and actions, and
that these actions transcend the historical vision of phago-
cytosis and structural support that has long been described in
the term ‘‘reactive gliosis.’’ Microglia are now recognized as
the prime components of an intrinsic brain immune system
and as such they have become a main focus in cellular neu-
roimmunology and neuroinflammation [1].
Microglia
Microglia are normally quiescent, brain macrophages and
represent the resident immuno-competent cells of the
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shown that under your homeostatic conditions microglia
are not derived from the bone marrow but from
haematopoietic stem cells in the yolk sac during embryo-
genesis [2]. Del Rio Hortega [3] first recognized the
pathological importance of microglia in the central nervous
system (CNS), and he also coined the name. They consti-
tute up to 10 % of the total cell population of the CNS. In
conditions of intact blood–brain barrier when blood-borne
cells are largely absent, microglia together with perivas-
cular cells are the first line of the brain’s immune defense
system. Any neuronal insult or damage induces an acti-
vation of resting microglial cells. Activated microglia
produce a variety of proinflammatory molecules, change
their morphology and, if cell death occurs, finally mature
into full-blown macrophages [4, 5].
This morphological change has been well documented
in the facial nerve transection model, where microglial
activation can be assessed in an environment without
blood–brain barrier disruption or migration of new bone
marrow-derived macrophages. The model demonstrates the
capacity of resident microglia to undergo morphological
changes and activation with expression of new surface
markers and to proliferate around motor neurons of the
facial nucleus [6].
Microglia activation in vivo occurs as a graded
response. The transformation of microglia into potentially
cytotoxic cells is under strict control, mainly in response to
neuronal or terminal degeneration, or both. Activated
microglia are mainly scavenger cells but also perform
various other functions in tissue repair and neural regen-
eration [7]. They form a network of immune alert resident
macrophages with a capacity for immune surveillance and
control. Activated microglia can destroy invading micro-
organisms, remove potentially deleterious debris, promote
tissue repair by secreting growth factors and thus facilitate
the return to tissue homeostasis. An understanding of
intercellular signaling pathways for microglia proliferation
and activation could form a rational basis for targeted
intervention on glial reactions to injuries in the CNS; for an
extensive review on microglia see [7–10].
Activated microglia and neuroinflammation
in the neuropathology of parkinsonian disorders
Idiopathic Parkinson’s disease
The main pathological finding in IPD (idiopathic Parkin-
son’s disease) is the degeneration of dopaminergic pro-
jections from the substantia nigra pars compacta to the
caudate nucleus and putamen (striatum). Intraneuronal
Lewy bodies and Lewy neurites composed of the protein a-
synuclein are the pathological hallmarks of the disease.
However, the neuropathological changes are not confined
to the substantia nigra [11]. This is reflected in a staging
system for IPD proposed by Braak [12]. According to
Braak, the neuropathological process in PD, as represented
by a-synuclein-immuno-positive Lewy neurites and Lewy
bodies, first occurs in the dorsal IX/X motor nucleus and
olfactory bulb (stage 1). From the medulla oblongata, it
spreads into the pons and midbrain (stages 2 and 3) and
eventually into the anterior cingulate, association temporal
mesocortex and neocortex (stages 4–5), and finally primary
cortical areas (stage 6). There is emerging evidence that the
spread of the protein aggregate might follow a propagation
mechanism reminiscent of human prion disease [13].
In idiopathic Parkinson’s disease activated microglia
have initially been described in the substantia nigra [14]
and more recently also in putamen, hippocampus,
transentorhinal cortex, cingulate cortex and temporal cor-
tex [15].
The exact contribution of microglial activation to the
degenerative process in IPD is presently not well under-
stood. There is evidence from humans [16] and monkeys
[17] exposed to the nigral toxin MPTP that after a discrete
insult progression of parkinsonian symptoms can occur,
and this is accompanied by a prolonged neuroinflammatory
response even years after the acute exposure. However, it is
possible that the activation of microglia has different
functions (detrimental/beneficial) at the various stages of
the disease. Although neuropathologically associated with
the degenerative process, it is not necessarily responsible
for it.
Atypical parkinsonian disorders
In multiple system atrophy (MSA) typical histopathologi-
cal changes consist of neuronal loss in the nigrostriatal and
olivopontocerebellar pathways with a-synuclein-positive,
argyrophilic staining, glial cytoplasmic inclusions associ-
ated with reactive astrocytes and activated microglia [18–
20] .
In PSP (progressive supranuclear palsy) there is atrophy
of the brainstem, internal globus pallidus, amygdala,
frontal and parietal lobe, and nigral depigmentation.
Microscopically, neuronal loss is found in brainstem ocu-
lomotor nuclei, pallidum, substantia nigra, subthalamic
nucleus, and frontal cortex. The pathological hallmarks of
PSP are intraneuronal neurofibrillary tangles (NFTs)
composed of abnormally phosphorylated microtubule-as-
sociated tau-protein and neuropil threads [21]. The cell loss
in PSP is accompanied by microglial activation [22].
Gross pathological findings in CBD (corticobasal
degeneration) include narrowing of cortical gyri often in a
peri-Rolandic distribution. The superior frontal gyrus and
inferior parietal area are usually most affected while the
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inferior frontal gyri, temporal, and occipital lobes are
spared. The atrophy is characteristically asymmetric [23]
and detailed analysis of the distribution of the microglial
burden shows correlations with the anatomical regions
affected in CBD [22].
As shown in these studies referenced above, the neu-
ropathology of parkinsonian disorders is closely associated
with microglial activation. The exact role of neuroinflam-
mation in neurodegenerative disorders, however, is
unclear. Post-mortem studies and animal experiments have
numerous methodological limitations; for a review see
[24].
In vivo imaging in man using positron emission
tomography (PET) can overcome some of these, and the
principles and applications are detailed below.
PET imaging of inflammation in parkinsonian
syndromes
One of the molecules expressed during microglial activa-
tion is the mitochondrial translocator protein 18 kDa
(TSPO), formerly known as the ‘peripheral benzodiazepine
binding site’ (PBBS) [25, 26]. This protein is predomi-
nantly located on the outer mitochondrial membrane, and
has numerous functions including steroid biosynthesis and
protein transport. It is distinct from the GABA A–receptor
complex, the site of central benzodiazepine binding.
PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methyl-
propyl)-3-isoquinolinecarboxamide), a highly specific
TSPO ligand, exhibits low binding in the normal brain,
while increased binding is indicative of increased TSPO
expression in microglia following neuronal injury [27, 28]
(Fig. 1). The 11C-labeled (R)-isomer of PK11195 can thus
be used to image activated microglia in vivo. While [11C]-
(R)-PK11195 is the best pre-clinically and clinically
characterized PET ligand to image microglial activation,
new, often [18F]-based, radiotracers for microglial acti-
vation have been developed recently, but so far have only
been evaluated to a limited extent in a clinical context
[29, 30].
In Parkinson’s disease increased [11C]-(R)-PK11195 BP
(binding potential) has been shown using ROI (region of
interest) and SPM (statistical parametric mapping)-based
analyses in the striatum, thalamus, pons, frontal and cin-
gulate cortex in 18 PD patients compared to 11 controls
[31] (Fig. 2). There was no correlation of the extent of
microglial activation with clinical severity or findings on
[18F]-DOPA PET. Eight of the patients were followed up
longitudinally over 24 months, and, although the disease
had clinically progressed, there was no significant change
in the extent of microglial activation. In contrast, Ouchi
and colleagues [32] studied 10 early, drug-naı¨ve PD
patients and showed increased [11C]-(R)-PK11195 BP in
the midbrain, which was negatively correlated with dopa-
mine transporter binding measured by [11C]-CFT PET and
positively correlated with motor severity. Differences in
methodology as well as motor severity (mean UPDRS
motor score 32.0 compared to 10.4) may explain the dif-
ferences in distribution of [11C]-(R)-PK11195 binding and
other findings between these two studies.
Fig. 1 Schematic drawing of
microglial activation with
increased expression of TSPO
in mitochondria, and binding of
PK11195 to TSPO (modified
after [26])
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A recent study in six patients with PD in very early
stages (mean UPDRS motor score 7.2) confirmed the
results of increased striatal [11C]-(R)-PK11195 binding as
by Gerhard et al. This study also included patients with
dementia with Lewy bodies, in whom widespread cortical
microglial activation was seen in addition to subcortical
changes [33].
Edison and colleagues investigated the relationship
between microglial activation, amyloid deposition and
glucose metabolism in patients with Parkinson’s disease
with and without dementia [34]. The PD patients with
dementia showed widespread microglia activation in basal
ganglia and cortical regions, which was only slightly more
pronounced than in the PD patients without dementia.
Interestingly, in the demented Parkinson’s disease patients
an inverse correlation between cortical microglia activation
and scores on the Mini Mental State examination, a neu-
ropsychological test, could be demonstrated as well as a
significant overlap with regions in which glucose metabo-
lism was decreased.
In contrast to studies referenced above Koshimori and
colleagues recently published data that did not clearly show
an increase of TSPO expression in Parkinson’s disease
patients as compared to healthy controls, using the second
generation TSPO tracer [18F]-FEPPA [35]. However, this
study only included the caudate nucleus and putamen as
regions of interest and cortical or brainstem signal might
have been missed.
The first in vivo study in atypical parkinsonian disorders
to demonstrate elevated [11C]-(R)-PK11195 binding was
conducted in five patients with multiple system atrophy
(MSA) compared to controls [36]. Here, increased BP in
caudate nucleus, putamen, substantia nigra and pons as
well as cortical regions was measured.
In a PET imaging sub-study of a randomized placebo-
controlled trial of minocycline in patients with MSA,
treatment with minocycline was associated with reductions
in [11C]-(R)-PK11195 binding, but no clinical benefit was
shown in the overall study [37] (Fig. 3). However, this
study provided proof-of-concept for the use of PK11195
PET in monitoring treatment effects of potential anti-in-
flammatory agents in neurodegenerative disorders.
Recently one of the new TSPO PET ligands has been
used to measure microglial activation in Parkinson’s dis-
ease patients treated with AZD3241, a selective and irre-
versible inhibitor of myeloperoxidase with the putative
mode of action of a reduction of sustained neuroinflam-
mation through reduced oxidative stress [38]. Using [11C]-
PBR28 PET the authors reported a reduction of distribution
volume of the radioligand after 4 and 8 weeks of treatment
Fig. 2 Transverse and coronal
sections of binding potential
maps coregistered to the
individual MRI. In the PD
patient (a, b), binding is
increased in the basal ganglia,
pons and frontal regions, while
the healthy control person (c,
d) only shows constitutive
[11C](R)-PK11195. Binding in
the thalamus and pons. The
color bar denotes binding
potential values from 0 to 1.
Modified with permission from
[31]
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compared to the placebo group where no change was
found.
So far, however, there is no published study comparing
[11C]-PBR28 binding in healthy controls and patients with
Parkinson’s disease and it is therefore currently unknown
whether 11C-PBR28 increases in PD patients follow a
similar pattern as in studies with [11C]-(R)-PK11195.
PET studies using[11C]-(R)-PK11195 in parkinsonian
disorders with tau-pathology were also able to show
prominent microglial activation in vivo. In progressive
supranuclear palsy, elevated [11C]-(R)-PK11195 BP was
observed in the caudate, putamen, pallidum, substantia
nigra, midbrain, thalamus, cerebellum and frontal lobe
[39]. In the two patients who were rescanned after
6–10 months the PET signal remained stable.
Similarly, four patients with CBD showed increased
[11C]-(R)-PK11195 BP in caudate, putamen, substantia
nigra and frontoparietal cortex [40].
In a recent study [41] the relationship of increased
putaminal [11C]-(R)-PK11195 BP in patients with MSA-P
and PSP with MR markers of tissue damage such as
apparent diffusion coefficient was investigated; here,
microglial activation did not correlate with putaminal water
diffusivity.
Other targets than TSPO to image
neuroinflammation with PET
Over the last few years targets involved in the neuroin-
flammatory process in neurodegenerative disease other
than the TSPO have been identified that are currently
evaluated using PET ligands.
One very interesting target is the cannabinoid receptor
type 2 (CB2R), which is involved in peripheral immune
system function, and is also upregulated in CNS disorders
showing microglial activation [42], including Alzheimer’s
Fig. 3 Longitudinal changes in
[11C]-(R)-PK11195 binding
potential (BP) seen in a study of
minocycline therapy in patients
with multiple system atrophy
(MSA). Images are transverse
BP maps coregistered to
structural T1-weighted MR
images at baseline (a) and after
24 weeks of treatment (b).
Modified with permission from
[37]
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disease [43] and animal models of Huntington’s disease
[44]. This has led to the development of specific ligands,
such as [11C]-NE40, which shows binding to the human
CB2R overexpressed in rodent striatum in preclinical PET
studies [45]. First in man to symmetry studies showed a
swift brain uptake [46], however, at the time of writing, no
clinical data on CB2R PET studies in PD have been
published.
In addition to microglial activation, proliferation of
astrocytes as part is seen in several neurodegenerative
conditions including AD, and is associated with increased
expression of monoamine oxidase B (MAO B) [47].
Autoradiographic studies in post-mortem AD tissue using
the radiolabelled selective MAO B inhibitor [11C]-L-de-
prenyl (selegiline) demonstrated specific binding to cortical
areas with large numbers of reactive astrocytes and
microglia [48]. The deuterium-substituted analog [11C]-
deuteriodeprenyl (DED) has been utilized as a PET tracer
due to its kinetic advantages, including increased sensi-
tivity [49].
So far no studies with this marker have been performed
in parkinsonian disorders, but in a study investigating MCI
(minimal cognitive impairment) and AD patients, [11C]-
DED binding was highest in MCI patients compared to
healthy controls and AD patients overall. PiB-(a PET
marker for amyloid) positive MCI patients had the highest
levels of DED binding while AD patients had the least [50].
This raises the possibility that astrocytosis may be an early
event in the pathogenesis of AD, a hypothesis supported by
a detailed pathological case study in which no relationship
was found between post-mortem binding of [3H]-PiB, [3H]-
PK11195 and [3H]-L-deprenyl in AD brain tissue [51].
Similarly, in a recent case report of a patient with memory
impairment and clinical motor neuron disease increased
binding of [11C]-DED on PET was suggestive of astrocy-
tosis [52].
Hence, imaging of astrocyte proliferation represents a
promising target for quantifying neuroinflammation in
several neurodegenerative conditions.
The purinergic receptor P2X7 plays in recognizing a-
synuclein, a key protein in Parkinson’s disease [53], and
currently PET ligands are been developed for the micro-
glial P2X7 (personal communication Bert Windhorst,
Amsterdam).
Conclusion/summary
[11C]-(R)-PK11195 PET is an imaging modality with the
ability to demonstrate one aspect of the neuropathology in
neurodegenerative disorders in vivo and longitudinally in a
minimally invasive fashion.
The studies mentioned above have demonstrated pattern
of microglia activation in different parkinsonian syndromes
that are in good agreement with the distribution of known
neuropathological changes in these disorders. Interestingly
the small number of longitudinal studies (between 4 weeks
and 24 months) did not show a significant change in the
extent of microglia activation although patients progressed
clinically.
The successful application of PET imaging for microglia
activation enables us to use an ‘‘in vivo pathology’’
approach that also allows to monitor treatment responses in
interventional trials.
Despite these interesting possibilities a number of open
questions remain. PET only captures one aspect of the
neuroinflammatory response, namely the expression of
TSPO. It is, however, highly likely that activated microglia
performs different functions at different stages of neu-
rodegenerative disorders.
The optimal method of analysis for PET data is also the
subject of debate, as the selection of an anatomically
defined reference region due to constitutive expression of
TSPO within the brain and potentially widespread pathol-
ogy in neurodegenerative disorders, is difficult. Methods
using kinetic analysis to identify a reference tissue cluster
have, therefore, been employed in the analysis of [11C]-(R)-
PK11195 PET data in neurodegenerative disease [54].
Lastly, as a [11C]-labeled tracer [11C]-(R)-PK11195 has
only a short half-life and necessitates a cyclotron on site for
tracer production, which limits wider clinical application.
Currently significant effort goes into the development of
novel TSPO ligands for PET imaging in neurodegenerative
diseases. Additionally, the recent finding of populations of
high- and low-affinity binders for TSPO ligands other than
[11C]-(R)-PK11195 has further complicated the analysis of
these data. Thus, studies utilizing such ligands require
analysis of TSPO binding affinity to correct for this factor.
Only further clinical evaluations and direct comparisons
with [11C]-(R)-PK11195 will show whether any of the new
putative TSPO tracers are indeed superior in the clinical
context. As there are known species differences in TSPO
binding, in vitro and preclinical animal data do not always
directly translate into clinical applications in humans.
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